Hospira to address misconceptions in EU Remicade biosimilar market
This article was originally published in Scrip
Hospira’s VP Biologics Paul Greenland says the company can become a leader in the infliximab market following its trail-blazing EU approval for a biosimilar monoclonal antibody. It will mobilize lessons already learned from its existing biosimilar products, such as ensuring that doctors don’t swallow peddled misconceptions about biosimilars. And, at least for the time being, the company is not discussing any radical plans to build on its first-mover advantage.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.